ARS Pharmaceuticals, Inc. cash flow to debt ratio of -177.29% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ARS Pharmaceuticals, Inc.'s free cash flow has decreased -1.42K% from $12.98M last year to $-171.21M, signaling decreasing performance

ARS Pharmaceuticals, Inc.'s debt to equity ratio is 1.57, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

ARS Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 1.57 today, signaling weakened financials

ARS Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

ARS Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

ARS Pharmaceuticals, Inc.'s profit margin has decreased (-2.33K%) in the last year from 8.97% to -200.00%, signaling decreasing performance

ARS Pharmaceuticals, Inc.'s short-term assets of $284.90M exceed its short-term liabilities of $39.15M

ARS Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ARS Pharmaceuticals, Inc.'s return on equity of -153.61%, is lower than 15.00%, indicating bad performance

ARS Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ARS Pharmaceuticals, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

ARS Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

ARS Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

ARS Pharmaceuticals, Inc.'s yearly earnings has decreased -2.24K% since last year from $8.00M to $-171.30M, signaling decreasing performance

ARS Pharmaceuticals, Inc.'s yearly revenue has decreased -5.46% since last year from $89.15M to $84.28M, signaling decreasing performance

ROIC -85.03% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ARS Pharmaceuticals, Inc.'s 3-year revenue CAGR of 300.09% is positive, indicating growing revenue over the past 3 years

ARS Pharmaceuticals, Inc. had revenue growth in only 1.00 out of 5 years, indicating inconsistent revenue performance

ARS Pharmaceuticals, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

ARS Pharmaceuticals, Inc. has insufficient data to evaluate this check.

ARS Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ARS Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ARS Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ARS Pharmaceuticals, Inc. is overvalued relative to its fair value price of -58.47 based on Earnings Fair Value model

ARS Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ARS Pharmaceuticals, Inc. has a price-to-book ratio of 12.33x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

ARS Pharmaceuticals, Inc. has a price-to-sales ratio of 7.63x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue